{"filing":{"accession_number":"0001140361-26-028368","cik":"0001275187","ticker":"ANGO","company_name":"ANGIODYNAMICS INC","form":"8-K","filing_date":"2026-07-14","report_date":null,"primary_document":"ef20077916_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1275187/000114036126028368/ef20077916_8k.htm"},"events":[{"id":17738,"run_id":15903,"accession_number":"0001140361-26-028368","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.97,"summary":"AngioDynamics issued a press release on July 14, 2026 announcing financial results for the fiscal fourth quarter and full year ended May 31, 2026, including net sales of $320.2M (9.4% growth), gross margin of 54.6%, adjusted EBITDA of $13.2M, and forward-looking guidance for fiscal 2027 net sales of $336.0M–$341.0M.","company_name":"ANGIODYNAMICS INC","ticker":"ANGO","filing_date":"2026-07-14","form":"8-K","submitted_at":null,"items":[{"id":16324,"accession_number":"0001140361-26-028368","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"AngioDynamics issued a press release on July 14, 2026 announcing financial results for the fiscal fourth quarter and full year ended May 31, 2026. The disclosure includes detailed quarterly and annual financial metrics (net sales of $320.2M for FY2026, gross margin of 54.6%, adjusted EBITDA of $13.2M), segment performance (Med Tech growth of 18.4%), and forward-looking guidance for fiscal 2027 ($336.0M–$341.0M in net sales). This is a standard earnings release disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T11:33:41.008545+00:00","company_name":"","ticker":null,"filing_date":""},{"id":16325,"accession_number":"0001140361-26-028368","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"AngioDynamics disclosed its fiscal fourth quarter and full-year 2026 financial results (ended May 31, 2026) via a press release furnished as Exhibit 99.1. The disclosure includes net sales of $320.2 million for the full year (9.4% growth), adjusted EBITDA of $13.2 million, and forward-looking guidance for fiscal 2027 net sales of $336.0M–$341.0M. This is a standard earnings release disclosing quarterly and annual financial results, which is material to investors assessing the registrant's financial performance and trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T11:33:41.008545+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16324,"accession_number":"0001140361-26-028368","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"AngioDynamics issued a press release on July 14, 2026 announcing financial results for the fiscal fourth quarter and full year ended May 31, 2026. The disclosure includes detailed quarterly and annual financial metrics (net sales of $320.2M for FY2026, gross margin of 54.6%, adjusted EBITDA of $13.2M), segment performance (Med Tech growth of 18.4%), and forward-looking guidance for fiscal 2027 ($336.0M–$341.0M in net sales). This is a standard earnings release disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T11:33:41.008545+00:00","company_name":"ANGIODYNAMICS INC","ticker":"ANGO","filing_date":"2026-07-14"},{"id":16325,"accession_number":"0001140361-26-028368","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"AngioDynamics disclosed its fiscal fourth quarter and full-year 2026 financial results (ended May 31, 2026) via a press release furnished as Exhibit 99.1. The disclosure includes net sales of $320.2 million for the full year (9.4% growth), adjusted EBITDA of $13.2 million, and forward-looking guidance for fiscal 2027 net sales of $336.0M–$341.0M. This is a standard earnings release disclosing quarterly and annual financial results, which is material to investors assessing the registrant's financial performance and trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T11:33:41.008545+00:00","company_name":"ANGIODYNAMICS INC","ticker":"ANGO","filing_date":"2026-07-14"}]}